Regent Pacific Group Limited operates as an investment holding company, directing capital towards businesses within the healthcare and life sciences sectors, primarily in European and Taiwanese markets. The company's activities are organized into two primary divisions: Biopharma and Corporate Investment. Within the Biopharma segment, the focus is on the entire lifecycle of pharmaceutical products, from initial research and development to manufacturing, marketing, and sales, specifically addressing treatments for urological conditions. This division is also involved in developing advanced artificial intelligence systems engineered to quantify the aging rate across molecular, cellular, tissue, organ, systemic, physiological, and psychological aspects. The Corporate Investment division, meanwhile, commits funds to both publicly traded and privately owned entities. Additionally, the company offers various management services.
—
Regent Pacific Group Limited operates as an investment holding company, directing capital towards businesses within the healthcare and life sciences sectors, primarily in European and Taiwanese markets. The company's activities are organized into two primary divisions: Biopharma and Corporate Investment. Within the Biopharma segment, the focus is on the entire lifecycle of pharmaceutical products, from initial research and development to manufacturing, marketing, and sales, specifically addressing treatments for urological conditions. This division is also involved in developing advanced artificial intelligence systems engineered to quantify the aging rate across molecular, cellular, tissue, organ, systemic, physiological, and psychological aspects. The Corporate Investment division, meanwhile, commits funds to both publicly traded and privately owned entities. Additionally, the company offers various management services.
—
Daily adjusted close
Regent Pacific Group Limited operates as an investment holding company, directing capital towards businesses within the healthcare and life sciences sectors, primarily in European and Taiwanese markets. The company's activities are organized into two primary divisions: Biopharma and Corporate Investment. Within the Biopharma segment, the focus is on the entire lifecycle of pharmaceutical products, from initial research and development to manufacturing, marketing, and sales, specifically addressing treatments for urological conditions. This division is also involved in developing advanced artificial intelligence systems engineered to quantify the aging rate across molecular, cellular, tissue, organ, systemic, physiological, and psychological aspects. The Corporate Investment division, meanwhile, commits funds to both publicly traded and privately owned entities. Additionally, the company offers various management services.